Alzheimer's disease (AD) is a progressive neurodegenerative disorder resulting in dementia and eventual death. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Cerebral amyloid angiopathy- related inflammation (CAA-ri) is an aggressive disease subtype of CAA with characteristic clinical and radiological findings. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
38/100
Small molecular weight compounds able to inhibit formation of tau oligomers and fibrils have already been tested for Alzheimer's disease (AD) treatment. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dugesia tigrina is a non-parasitic platyhelminth, which has been recently utilized in pharmacological models, regarding the nervous system, as it presents a wide sensitivity to drugs. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Traditional drug development for Alzheimer's disease (AD) is costly, time consuming and burdened by a very low success rate. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The evidence of strong pathological associations between type 2 diabetes and Alzheimer's disease (AD) has increased in recent years. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
To investigate the value of hydrogen proton magnet resonance spectroscopy ((1)H-MRS) in the differential diagnosis of multiple-domain amnestic mild cognitive impairment (M-aMCI) and vascular cognitive impairment with no dementia (VCIND); (1)H-MRS was performed in patients with M-aMCI and VCIND. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Sleep disorders appear to be frequent comorbidities in patients with frontotemporal dementia (FTD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
White Matter Disease is increasingly being recognized as an important cause of cognitive decline and dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Genetic and environmental protective factors and risks modulate brain structure and function in neurodegenerative diseases and their preclinical stages. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We studied neuroinflammation in individuals with late-life depression, as a risk factor for dementia, using [11C]PK11195 positron emission tomography (PET). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
More hallucinatory experiences, social isolation, and loneliness were found in the AD group than in the healthy control group. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia, closely linked to environmental predisposing factors such as diet, is a public health problem of increasing magnitude: currently there are more than 35 million patients with Alzheimer´s disease, and is expected to exceed 135 million by 2050. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is currently the most common incurable forms of dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
mRNA for inflammasome components (NLRP1, NLRP3, PYCARD, caspase 1, 5 and 8) and downstream effectors (IL-1β, IL-18) was up-regulated in severe and MILD AD. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
β-Amyloid (Aβ) oligomers may play an important role in the early pathogenesis of Alzheimer's disease: cognitive impairment caused by synaptic dysfunction. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
N-methyl-D-aspartate receptors (NMDARs) play a pivotal role in the synaptic transmission and synaptic plasticity thought to underlie learning and memory. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Ginkgo leaf is the most used form of supplement for cognitive ailments. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is an irreversible brain disorder characterized by progressive cognitive decline and neurodegeneration of brain regions that are crucial for learning and memory. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cellular proteomes are continuously undergoing alterations as a result of new production of proteins, protein folding, and degradation of proteins. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The research on aging and age-related diseases, especially the neurodegenerative diseases, is on the fast track. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Impaired protein degradation has been discussed as a cause or consequence of various neurodegenerative diseases, such as Alzheimer's, Parkinson's and Huntington's disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cells have developed an evolutionary obligation to survey and maintain proteome fidelity and avoid the possible toxic consequences of protein misfolding and aggregation. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Due to the rapid increase of the number in people with dementia, social costs of dementia are also expected to rise. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Care home residents are often frail with multiple comorbidities and cognitive impairment, most commonly caused by dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →